11 December.
The announcement of a new 10,000 sq m bio-incubator for the Edinburgh BioQuarter confirms the latest £24 million (E26.4 million) investment in the Scottish life sciences cluster.
The facility will be jointly funded by the UK Department for Business Innovation and Skills through the Strategic Investment Fund and Scottish Enterprise. Welcoming the announcement, Lena Wilson, chief executive of Scottish Enterprise, said: "The BioQuarter is one of the largest projects of its type in Europe and this funding will allow the partners to cement Scotland's position as one of the most dynamic locations for life sciences globally."
The bio-incubator is targeted at start-up and spin-out biotechnology companies, and will help to create 200 jobs in Edinburgh over the next five years. It will offer access to high-cost specialized equipment, advice, mentoring and expertise to support successful product development.
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.